| Views | |
|---|---|
| Evaluating the impact of bevacizumab as a targeted therapy in combination with standard chemotherapy on disease progression and treatment outcomes in ovarian cancer | 36 |
| May 2026 | June 2026 | July 2026 | August 2026 | September 2026 | October 2026 | November 2026 | |
|---|---|---|---|---|---|---|---|
| Evaluating the impact of bevacizumab as a targeted therapy in combination with standard chemotherapy on disease progression and treatment outcomes in ovarian cancer | 0 | 0 | 0 | 0 | 2 | 25 | 9 |
| Views | |
|---|---|
| 104-106.pdf | 6 |
| Views | |
|---|---|
| United States | 9 |
| Belarus | 4 |
| United Kingdom | 3 |
| Canada | 2 |
| Switzerland | 2 |
| Kazakhstan | 2 |
| United Arab Emirates | 1 |
| Bolivia | 1 |
| Ecuador | 1 |
| Hong Kong | 1 |
| Views | |
|---|---|
| Minsk | 3 |
| Greenville | 2 |
| Bern | 1 |
| Charlotte | 1 |
| Florence | 1 |
| Houston | 1 |
| La Paz | 1 |
| Little Elm | 1 |
| London | 1 |
| Quito | 1 |